Both approved labels advise against it, in the same words, and they mean it about every drug in this class.
Wegovy's label says coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. Zepbound's says the same about tirzepatide and any GLP-1 receptor agonist.12 That covers the brand-name combinations people ask about most: Ozempic with Mounjaro, Wegovy with Zepbound, or any pairing across those four.
Retatrutide has no label, so nothing says it there. It hits the same receptor as both of them and then two more.
The exception people have half-heard about is real but is not what they think: cagrilintide is not a GLP-1 drug at all, and combining it with one is a separate strategy being tested by pharmaceutical companies. That is a different question from stacking two incretins, and it is the one with evidence behind it.
Meanwhile, in our September capture, 18 of the sellers we tracked sold these pre-mixed, including one vial containing three compounds at once.3
Can you take two GLP-1 drugs together?
Not according to either label, and the wording is short, blunt and identical in substance.
Wegovy: coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. The safety and effectiveness of combining it with other weight-loss products have not been established.1
Zepbound: coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.2
Worth being precise about the wording, because it matters. "Not recommended" is not the same as contraindicated. A contraindication says do not do this because harm is established. "Not recommended" here means nobody has studied it, so there is no basis on which to recommend it. The absence is the point.
Can you add cagrilintide to a GLP-1?
Less an exception than a different question.
Cagrilintide is an amylin analogue. Amylin is a separate hormone from GLP-1, acting through different receptors, which is why combining the two is a pharmaceutical strategy rather than a mistake. Novo Nordisk's CagriSema pairs cagrilintide with semaglutide and has reported phase 3 results, and Lilly has an amylin programme of its own.
So "GLP-1 plus amylin" has companies, trials and published results behind it. "GLP-1 plus GLP-1" has neither.
One result from that programme is worth knowing before anyone treats combination as automatically better. In the only head-to-head trial, CagriSema missed non-inferiority against tirzepatide alone. A purpose-built combination, developed with matched dosing and proper escalation, did not beat a single drug. Our piece on that trial covers what it did and did not show.
Why two incretins does not mean twice the result
The dose-response curve answers this, and it flattens.
In SURMOUNT-1, tirzepatide produced 15.0% weight loss at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg.4 Tripling the dose from 5 to 15 mg bought about six percentage points, and the last step from 10 to 15 mg bought less than a point and a half.
Receptors do not respond linearly, and they saturate. Adding a second drug that acts on the same receptor is closer to a dose increase than to a new mechanism, which means you can expect the flat part of the curve and the steep part of the side effect curve at the same time.
Retatrutide adds glucagon receptor activity that the others lack, so a tirzepatide and retatrutide combination is not purely redundant. What that extra receptor does alongside a second incretin, at any dose, is anyone's guess.
Why people reach for a second drug
Almost always a stall, and the stall is usually the trial curve behaving normally.
Weight loss on these drugs is fast early and then slows. In SURMOUNT-1 the curve was still descending at 72 weeks but far more gradually than in the first few months.4 A plateau at month six is not failure, and it is not evidence that the drug has stopped working.
The three responses to a stall, in order of how much evidence sits behind them: finish the escalation you are on, if you are not at the top dose yet. Change drug. Add a second drug.
People reach for the third because it feels like doing more, and it is the only one of the three nobody has tested.
Switching is studied. Stacking is not.
People use the words interchangeably. The evidence does not.
Switching from an injectable to another incretin has been through trials. SURMOUNT-MAINTAIN moved people from a maximum tolerated dose down to 5 mg and measured what happened over a further year. Orforglipron's programme includes a trial of people transitioning directly from injectable therapy.
Nothing comparable exists for running two at once. The entire difference between a studied question and an unstudied one, in this class, is whether you stop the first drug.
The overlap problem when you switch
The part that catches people who think they are switching rather than stacking.
These drugs have long half-lives. Semaglutide's elimination half-life is about a week, tirzepatide's about five days, and retatrutide's about six.125
Clearing a drug takes roughly five half-lives, which puts semaglutide at about five weeks, retatrutide at about a month, and tirzepatide at about 25 days. Two weeks after a last semaglutide injection, a meaningful amount is still there.
Start the second drug the week after stopping the first and you are, pharmacologically, taking both for several weeks. People who would never describe themselves as stacking do exactly that during a switch, and the gut effects arrive looking like the new drug being badly tolerated.
If you are switching, the overlap is the part to discuss with a prescriber, and it is the reason a switch is not simply one injection replacing another.
What are the risks of stacking GLP-1s?
Gastrointestinal effects are the ones that stack, and they are the reason people end up in an emergency department.
Both drugs slow gastric emptying. Both cause constipation in a meaningful share of users: in the pooled tirzepatide trials, 11.7% to 17.1% depending on dose. Severe gastrointestinal reactions ran 1.7% to 3.1% against 1.0% on placebo, rising with dose.2
Two drugs doing the same thing to the same system, started at the same time, without the twenty-week escalation that made those rates tolerable in the trials, is how a manageable side effect becomes an obstruction. The forum accounts of people presenting with severe constipation after combining maximum doses are consistent with the mechanism rather than surprising.
The second path is dehydration. Vomiting and diarrhoea on a drug that has already reduced how much you drink leads to volume depletion, and both labels carry warnings about acute kidney injury from exactly that sequence. Our dehydration guide follows that path in detail.
Who sells pre-mixed GLP-1 blends?
Eighteen of the sellers we tracked in our September capture offered these pre-mixed blends.
In our September capture, 26 listings across 18 sellers combine two or more incretin or amylin compounds in a single vial.3 Most pair cagrilintide with semaglutide or retatrutide, which at least matches the pharmaceutical strategy. Some do not.
One listing contains tirzepatide, semaglutide and cagrilintide together. That is two GLP-1 receptor agonists in the same vial, which is the specific combination both labels advise against, plus an amylin analogue, at fixed ratios chosen by a seller.
Several are sold under invented brand names that do not disclose the contents without reading the description. Our vendor code guide covers the naming problem, and the blend question is sharper than usual here: a fixed-ratio vial removes your ability to adjust one component, which is the thing you would most want to do if the combination is not agreeing with you.
What to do if you are already doing it
Whether to continue is a prescriber's call. Three things are worth knowing either way.
Know what you took and when. If you present to a clinician with severe abdominal symptoms, the single most useful thing you can hand over is a list of compounds, doses and dates. Our guide on telling a doctor covers how that conversation tends to go.
Know the red flags: abdominal pain that will not ease, especially with vomiting and no bowel movement, which is the obstruction pattern. Passing very little urine. Faintness on standing. Severe pain radiating to the back.
And if you are having surgery or any sedation, say what you are on. Both labels now carry warnings about delayed gastric emptying and aspiration under anaesthesia, and two drugs doing it is not less of a problem than one.
Common questions
Can you take Mounjaro and Ozempic together?
No. Both labels advise against coadministration with any other GLP-1 receptor agonist, and Mounjaro and Ozempic are both in that class. The same applies to Wegovy with Zepbound, or any other pairing across those four brands.
Can you take tirzepatide and retatrutide together?
No trial has tested it in anyone. Both approved labels in this class advise against combining their drug with any other GLP-1 receptor agonist, and retatrutide acts on that receptor along with two others. The combination has no published safety or efficacy data at any dose.
Is combining GLP-1 drugs dangerous or just pointless?
Both, in different ways. The dose-response curve flattens, so a second drug on the same receptor behaves more like a dose increase than a new mechanism. The gastrointestinal effects add up, and severe constipation leading to obstruction is the pattern that sends people to hospital.
Why is CagriSema allowed to combine two drugs then?
Because cagrilintide is an amylin analogue, not a GLP-1 receptor agonist, so it acts on a different system. That is a combination with trials behind it rather than two drugs doing the same job. Even so, it missed non-inferiority against tirzepatide alone in the only head-to-head trial.
Is it a contraindication or just not recommended?
Not recommended, which is weaker and more honest. A contraindication means harm is established. Not recommended here means nobody has studied it and there is no basis for a recommendation.
Can I add cagrilintide to retatrutide?
It is the pairing most of the pre-mixed vials use, and it mirrors what pharmaceutical companies are developing. It has still never been tested in that specific combination, and a fixed-ratio vial takes away your ability to change one component without changing both.
What happens if I stack and feel terrible?
The usual first problem is gut effects compounding: constipation, nausea and vomiting at the same time. Pain that will not ease, especially with vomiting and no bowel movement, needs urgent attention rather than a forum thread.
I stalled. Should I add a second drug?
A plateau is the normal shape of these curves rather than a sign the drug stopped working. Of the three responses available, finishing your escalation and switching drugs both have trials behind them. Adding a second drug has none.
If I switch from one to the other, do I need a gap?
That is a prescriber question, and the reason it matters is half-lives: roughly a week for semaglutide, five days for tirzepatide, six for retatrutide. Clearing a drug takes about five half-lives, so starting the next one immediately means both are present for several weeks.
Do blends save money?
Sometimes, and that is not the question that should decide it. A fixed-ratio vial locks the proportion of two compounds chosen by a seller, which is the thing you would most want to change if you were not tolerating it.
How many sellers offer these pre-mixed?
Eighteen of the sellers we track, across 26 listings, in our September capture. One vial contains three compounds, including two GLP-1 receptor agonists together.
Sources
- Wegovy (semaglutide) prescribing information, Limitations of Use. accessdata.fda.gov. The approved label. States that coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, and that the safety and effectiveness of coadministration with other products intended for weight loss have not been established.
- Zepbound (tirzepatide) prescribing information, Limitations of Use and Adverse Reactions. pi.lilly.com. The approved label. States that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Also the source for constipation at 11.7% to 17.1% by dose and severe gastrointestinal reactions at 1.7%, 2.5% and 3.1% by dose against 1.0% on placebo.
- Peptide Decoding vendor price capture, 29 September 2026. peptidedecoding.com/prices. Our own data, counting one priced product at one seller as a listing: 7,534 listings across 151 sellers. Twenty-six listings across eighteen sellers combine two or more incretin or amylin compounds in a single vial, most pairing cagrilintide with semaglutide or retatrutide. One listing combines tirzepatide, semaglutide and cagrilintide.
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine 2022;387:205-216. doi:10.1056/NEJMoa2206038. Phase 3 trial, 2,539 adults, 72 weeks. Weight loss of 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg against 3.1% on placebo, which is the dose-response flattening described here.
- Retatrutide pharmacokinetics, as reported in the phase 2 trial and the manufacturer's medical information. The phase 2 publication states that the pharmacokinetics of retatrutide are dose-proportional with a half-life of approximately 6 days, enabling weekly administration; Lilly's medical information pages give the same figure from a phase 1 study in healthy participants. Semaglutide's elimination half-life of about 1 week and tirzepatide's of about 5 days are stated in section 12.3 of their respective labels, sources 1 and 2.
Citing this page. Peptide Decoding. Can You Stack Tirzepatide and Retatrutide? Label wording as cited; blend listings from the 29 September 2026 capture. https://peptidedecoding.com/guides/stacking-glp1s